Moe Alsumidaie’s Post

Revolutionizing clinical trials: Accenture's strategic investment fuels QuantHealth's AI innovation 💊 🔬 Accenture has strategically invested in QuantHealth, an AI-powered clinical trial design company, aiming to expedite drug development for pharmaceutical and biotech companies. QuantHealth's innovative simulation platform, trained on extensive datasets, predicts trial outcomes, optimizing drug development decisions and potentially reducing costs. With clinical trials representing a significant investment, this collaboration seeks to revolutionize the pharmaceutical industry by harnessing AI-designed simulations. QuantHealth addresses the high failure rate of drugs in the clinical stage, amounting to a $50 billion annual loss for pharmaceutical companies. With an innovative clinical simulator powered by AI, QuantHealth predicts individual patient responses in clinical trials, enabling comprehensive trial outcome predictions and design optimization. Leveraging a unique AI engine and an extensive dataset of 350 million patients and 700,000 therapeutics, QuantHealth achieves an 86% accuracy in predicting clinical trial results. #pharmainnovation #clinicaltrials #digitaltransformation #pharmainnovation #digitalpharma #biopharma #pharmatech #healthcaretechnology #digitalhealth #healthcareinnovation

The U.S. International Trade Commission released a corrected version of its COVID-19 Diagnostics and Therapeutics: Supply, Demand and TRIPS Flexibilities Report in December 2023. Chapter 7 provides a summary of views of interested parties, including a section on jobs related to the pharmaceutical and biotech industries. The report discusses the complexities of defining COVID-19 diagnostics and therapeutics, the challenges in their development and commercialization, and the disparities in access and availability among countries of different income groups. It also explores the use of voluntary and compulsory licenses to access intellectual property associated with COVID-19 therapeutics. The report highlights the wide disparity among countries in their ability to access COVID-19 diagnostics and therapeutics, and the impact of factors such as access to intellectual property, prices, regulatory approvals, healthcare infrastructure, and government healthcare priorities. The report suggests that academic literature on the effects of patent protection, compulsory licenses, and the Medicines Patent Pool would benefit from additional research, particularly in relation to COVID-19 diagnostics and therapeutics.

Learn how a #biopharma sponsor utilized Judi for DSMB in a #raredisease trial. Discover the power of #ai in optimizing #clinicaltrial workflows. Explore how a European #pharmaceutical company leveraged Judi for Eligibility in a cutting-edge #psychedelics clinical program. Read or download a wealth of case studies, blog posts, and whitepapers on our Insights page. Judi.io 👇

Exciting advancements in AI are revolutionizing the pharmaceutical industry, enhancing drug discovery, clinical trials, and personalized medicine. This aligns perfectly with Allex.ai's mission to bring efficiency and innovation to project management. Discover how AI is transforming the pharma landscape in this insightful article. 🚀#PharmaInnovation #ArtificialIntelligence #ProjectManagement #Allexai https://lnkd.in/dzgKhSrS

♂ https://clinfinite.com/♂ ☑ Clinfinite Solutions is a Contract Research Organization (CRO) dedicated to delivering regulatory and clinical development solutions tailored for the biopharmaceutical and medical device sector. ☑ With a comprehensive suite of services, Clinfinite assists organizations in enhancing their clinical trial processes and operational efficiency. ☑ The company's expertise spans the entire spectrum of clinical development, facilitating the expedited advancement of novel therapies and medical interventions. ☑ Clinfinite's specialized services contribute to regulatory compliance, data management, monitoring, and overall project management, ensuring that clients can navigate the complexities of drug and device development with confidence. ☑ By partnering with Clinfinite Solutions, biopharmaceutical and medical device companies can benefit from streamlined operations, accelerated timelines, and the efficient execution of clinical trials, ultimately contributing to advancements in healthcare innovation. #ClinfiniteSolutions #contractresearchorganization #cro #innovation #biopharmaceutical # clinical trials

Dear Friends, Some interesting statistics on 1H 2024 licensing partnerships in the biopharma (defined to include companies developing therapeutics as well as technology platforms engaged in drug discovery and R&D) and medtech (defined to include companies developing medical devices, therapeutic digital health, commercial R&D tools, and diagnostics) sectors from J.P. Morgan’s Q2 2024 U.S. Biopharma Licensing and Venture Report and Q2 2024 U.S. Medtech Licensing and Venture Report, respectively. ·      BioPharma Licensing Deals o  In 1H 2024, $76.3 billion (in total deal value) licensing deals were announced in the biopharma sector, with only 6% of deal value attributed to upfront payments made upon deal signing. Therefore, the bulk of value in these deals was attributed to contingent payments, such as payments made upon achievement of milestones. o  Of these announced licensing deals announced, $30.5 billion (in total deal value) involved biologics (such as antibodies, DNA, RNA, ADC, etc.), $17.3 billion (in total deal value) involved small molecules, and $9.0 billion (in total deal value) involved genomics, sequencing, or screening modalities. o  During 1H 2024, median upfront cash (and equity) payments in licensing deals with  large-cap biopharma (defined as market cap of $50 billion+) was highest ($200 million) in deals involving Phase III assets, which is a shift from 2023, when the median upfront was highest ($310 million) in deals involving Phase II assets. o  Based on 1H 2024 activity, it is anticipated that biopharma licensing deals will be down in 2024 as compared to the full year 2023, when $181.9 billion (in total deal value) was announced in the sector. ·      Medtech Licensing Deals o  In 1H 2024, $1.8 billion (in total deal value) licensing deals were announced in the medtech sector, with only 6% of deal value attributed to upfront payments made upon deal signing. Therefore, as in the biopharma sector, the bulk of value in these deals was attributed to contingent payments. o  Based on 1H 2024 activity, it is anticipated that medtech licensing deals will be substantially down in 2024 as compared to the full year 2023, when $12 billion (in total deal value) was announced in the sector. #wearemorganlewis, #MLLifeSci, #biopharma, #medtech

Title: Optimizing the Compass: Streamlining Clinical Trial Management and Monitoring for Biotech and Pharma Success Navigating the complexities of clinical trial management and monitoring (CTMM) is crucial for biotech and pharmaceutical companies seeking to bring life-saving treatments to patients. At eMIA, we recognize the evolving landscape of clinical trials and offer customized CTMM plans tailored to specific needs. Leveraging technology, such as cloud-based platforms and advanced analytics, optimizes data collection and analysis while ensuring regulatory compliance. However, the human touch remains indispensable, as our experienced clinical research professionals collaborate with clients to develop monitoring plans, assemble skilled trial teams, and foster clear communication channels. Investing in CTMM facilitates efficient trial execution, accelerates drug development timelines, and ultimately enhances patient access to vital treatments. Read the full article @ https://lnkd.in/eSu3ncrG

Are there financial benefits to employing digital endpoints in clinical trials? Joseph A. DiMasi et al. explored this question in their recent paper. 📈 They highlight that despite the need for an upfront investment in digital endpoints, endpoints yield strong expected net present value (eNPV) and ROI for the pharmaceutical industry. ⬆️ When digital endpoints are used, the increase in eNPV for phase 2 trials ranged from $2.2-$3.3 million, with ROIs ranging from 32-48%. Read in full: https://lnkd.in/e9dTMgfA #DigitalBiomarkers #WearableTechnology

Our selected services include expertise with Biomarkers & Surrogate Endpoints, Regulatory Affairs FDA & EMA, Medical Affairs & Clinical Research, Due Diligence, and Trial Management & Trial Rescue. BBCR’s Strategic Clinical Innovation OrganizationSM (SCIO) method is explicitly designed to help pharmaceutical innovators address their concerns and maneuver around evolving challenges. SCIOSM identifies time and cost […]